Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
Summary
This study enrolls patients who have relapsed/advanced hepatocellular carcinoma (HCC, BCLC stage C). The HCC tumor relapsed or metastasized through the body after standard treatment or the patients cannot receive standard treatment under current conditions. This research study uses specific HCC antigens CD8+ T cells, a new experimental treatment. The purpose of this study is to evaluate the safety and tolerance as well as the potential clinical efficacy of an adoptive transfer of CD8+ T cells, sorted with human leukocyte antigen (HLA)-peptide multimers and specific for Glypican (GPC)-3 /New York Esophageal Squamous-1 (NY-ESO-1) /alpha-fetoprotein (AFP) antigens and cultured in vitro, to patients suffering from relapsed/advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2017-05-01
- Primary completion
- 2018-12-30
- Completion
- 2019-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HCC antigens-specific CD8+ T lymphocytes | Cell therapy | 3e+07 unknown | — |
| Subject | HCC antigens-specific CD8+ T lymphocytes | Cell therapy | 6e+07 unknown | — |
| Subject | HCC antigens-specific CD8+ T lymphocytes | Cell therapy | 9e+07 unknown | — |
| Background | S-1 | Small molecule | 40 mg | — |
| Background | S-1 | Small molecule | 60 mg | — |
| Background | aldesleukin | Protein / enzyme biologic | 25000 iu/kg | — |